Multiple System Atrophy Clinical Trial
Official title:
Randomized, Double-blind, Sham-controlled to Evaluate the Effects of an Automated Abdominal Binder in Improving Orthostatic Tolerance in Autonomic Failure Patients With Disabling Orthostatic Hypotension
The automated inflatable abdominal binder is an investigational device for the treatment of orthostatic hypotension (low blood pressure on standing) in patients with autonomic failure. The purpose of this study is to determine safety and effectiveness of the automated abdominal binder in improving orthostatic tolerance in these patients.
Status | Recruiting |
Enrollment | 31 |
Est. completion date | December 1, 2024 |
Est. primary completion date | September 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 80 Years |
Eligibility | Inclusion Criteria: - Male and female subjects, age 40-80 years. - Possible or probable Multiple Systems Atrophy and Pure Autonomic Failure as defined by Consensus Criteria. - Neurogenic orthostatic hypotension defined as a =30-mm Hg decrease in SBP within 3 minutes of standing associated with impaired autonomic reflexes determined by autonomic testing in the absence of other identifiable causes, and - Moderate to severe orthostatic symptoms, defined as an Orthostatic Hypotension Symptom Assessment (OHSA) composite score =4 (self-rating Likert scale of 0 to 10, with 0 reflecting absence of symptoms), within the first 10 minutes of the screening orthostatic stress test, and that have an impact in quality of life, as defined by the patient. - Able and willing to provide informed consent. Exclusion Criteria: - Pregnancy. - Systemic illnesses known to produce autonomic neuropathy, including but not limited to diabetes mellitus, amyloidosis, monoclonal gammopathies, and autoimmune neuropathies. - History of known aortic aneurisms, thoracic, abdominal or pelvic surgery in the past 6 months; symptomatic abdominal or inguinal hernias; severe gastroesophageal reflux; recent fractures or fissures of ribs, thoracic or lumbar spine; medical devices implanted on the abdominal wall or abdomen that would interfere with the binder; known abdominal or pelvic tumors, cysts or enlarged spleen; intolerance to any increase in intraabdominal pressure. - Pre-existing sustained supine hypertension =180/110. - Bedridden patients or those who are unable to stand due to motor impairment or severe orthostatic hypotension. - Clinically unstable coronary artery disease (recurrent angina despite medical therapy), or major cardiovascular or neurological event in the past 6 months (myocardial infarction, stroke or transient ischemic attacks). - Concomitant use of anticoagulants |
Country | Name | City | State |
---|---|---|---|
United States | Autonomic Dysfunction Center/ Vanderbilt University Medical Center | Nashville | Tennessee |
Lead Sponsor | Collaborator |
---|---|
Vanderbilt University Medical Center | National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Orthostatic tolerance | orthostatic tolerance is defined as the area under the curve of the upright systolic blood pressure (AUCSBP) during the Morning Orthostatic Trials | After 10 minutes of standing (or as tolerated) during the Morning orthostatic trial on the automated binder/sham study day | |
Primary | Orthostatic Hypotension Symptom Assessment (OHSA) Score | The Orthostatic Hypotension Symptom Assessment (OHSA) Score is the part I of the Orthostatic Hypotension Questionnaire (OHQ). It consists of six questions, each rating the intensity of one characteristic symptom of orthostatic hypotension: 1. Dizziness, lightheadedness, feeling faint, or feeling like you might black out; 2. Problems with vision (blurring, seeing spots, tunnel vision, etc.); 3. Generalized weakness; 4. Fatigue; 5. Trouble concentrating; and 6. Head/neck discomfort.The items are scored on an 11-point Likert scale from 0 to 10, with 0 indicating no symptoms and 10 indicating the worst possible symptoms. Composite score is the average of the item scores obtained at the post-intervention stand period during the Morning Orthostatic Trials | After 10 minutes of standing (or as tolerated) during the Morning orthostatic trial on the automated binder/sham study day | |
Secondary | Upright time | Sum of standing and walking times | After 10 minutes of standing and 15 minutes waking (as tolerated) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03593512 -
Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy
|
N/A | |
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Recruiting |
NCT02897063 -
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
|
Phase 1 | |
Not yet recruiting |
NCT00758849 -
Fipamezole in Neurogenic Orthostatic Hypotension
|
Phase 2 | |
Completed |
NCT01155492 -
Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease
|
N/A | |
Recruiting |
NCT04431713 -
Exenatide Once-weekly as a Treatment for Multiple System Atrophy
|
Phase 2 | |
Completed |
NCT04184063 -
Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
|
Phase 2 | |
Recruiting |
NCT05121012 -
Synaptic Loss in Multiple System Atrophy
|
||
Terminated |
NCT03589976 -
A Futility Trial of Sirolimus in Multiple System Atrophy
|
Phase 2 | |
Recruiting |
NCT04706234 -
Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
|
||
Completed |
NCT00368199 -
Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes
|
N/A | |
Recruiting |
NCT04472130 -
Neurodegenerative Diseases Registry
|
||
Recruiting |
NCT04876326 -
Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy
|
N/A | |
Recruiting |
NCT04680065 -
GDNF Gene Therapy for Multiple System Atrophy
|
Phase 1 | |
Completed |
NCT03753763 -
Safinamide for Multiple System Atrophy (MSA)
|
Phase 2 | |
Recruiting |
NCT04250493 -
Insulin Resistance in Multiple System Atrophy
|
N/A | |
Recruiting |
NCT06072105 -
Medical Decision Making in Multiple System Atrophy
|
N/A | |
Terminated |
NCT02149901 -
Water and Sudafed in Autonomic Failure
|
Early Phase 1 | |
Terminated |
NCT00997672 -
Lithium in Multiple System Atrophy
|
Phase 2 |